The outlook of companies tied to flagship drugs like Viagra presents a complex investment landscape . While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the loss of exclusivity in key regions has introduced substantial volatility. Investors are now assessing the effect of rival medications